BPH Global Commences Cell-Based Testing for Seaweed Men’s Health Supplement

Binding Agreement Advances Project Giddy-Up Validation

BPH Global Ltd (ASX:BP8) has formalised a critical step in the development of its seaweed-based men’s health supplement, Project Giddy-Up, by signing a binding services agreement with Temasek Innovation Holdings Pte Ltd (TPIH) of Singapore. This contract sets in motion a structured, two-stage cell-based efficacy testing program aimed at scientifically validating the formulation’s biological activity related to male vitality, circulation, and hormonal support. The deal includes clear deliverables, intellectual property ownership retained by BPH, and a timeline extending through October 2026.

Targeted Biological Assays to Measure Male Vitality Effects

The testing program is designed to evaluate three key mechanisms underpinning male health. First, a phosphodiesterase-5 (PDE-5) inhibition assay will assess the formulation’s potential to improve blood flow and erectile function, a critical differentiator in the men’s nutraceutical space. Second, nitric oxide and cGMP pathway analysis will measure vascular relaxation effects in smooth muscle cells, relevant to circulation. Third, testosterone production assays in Leydig cells will probe endocrine support capabilities. Alongside efficacy, safety screening via ICP-MS will check for heavy metals such as arsenic, mercury, and lead, ensuring product quality.

This scientific approach reflects a relatively novel use of seaweed-based ingredients targeting multiple male vitality pathways, positioning Project Giddy-Up distinctively within a crowded market segment. The program will compare two candidate formulations, advancing the better performer to further development stages.

Strategic Steps Toward Regulatory Approval and Commercialisation

The completion of this testing phase is a pivotal milestone supporting BPH Global’s regulatory strategy to list Project Giddy-Up on the Australian Register of Therapeutic Goods (ARTG) as a TGA-listed complementary medicine (AUST L). The results will underpin the scientific evidence base required for regulatory submissions and help optimise the formulation ahead of commercial launch.

With the agreement now executed, BPH is poised to commence laboratory testing activities immediately, accelerating progress toward key development milestones. This move complements the company’s recent operational advances, including its Indonesian seaweed hub partnership and ongoing product prototyping efforts with national research agencies in Indonesia, which collectively bolster its vertically integrated nutraceutical supply chain.

Commercial and Intellectual Property Considerations

The agreement’s milestone-based fee structure totals SGD 29,000 plus GST, a modest investment relative to the potential commercial upside. Importantly, all intellectual property generated through the testing program remains with BPH, preserving strategic control over Project Giddy-Up’s proprietary formulation and data. Confidentiality provisions ensure sensitive information is protected throughout the collaboration.

As BPH Global advances its scientific validation, the market will be watching how the seaweed-based supplement performs against established male vitality markers, and whether it can carve out a niche amid growing consumer demand for natural health products. The company’s ability to navigate regulatory hurdles and translate lab success into market traction will be critical to unlocking value.